Zealand Pharma — November 2022
-
Det var en fin lille gennemgang af situationen. Finacial targets bliver fastholdt og ingen overraskelser. Jeg troet at BI var lidt længere fremme end det som blev fremlagt. Men det er min fejl at jeg ikke havde styr på dette.
-
Zealand Pharma Q3: Omsætning dykker og underskud vokser https://www.proinvestor.com/investornyt/903219/zealand-pharma-q3-omsaetning-dykker-og-underskud-vokser
-
Godmorgen
-
Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906, a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in patients with type 2 diabetes (T2D) at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD).
-
@Pensionisten - gider du venligst uddybe - tak!
-
Plus disse fire begivenheder:
Presented preclinical data at the Annual Meeting of the Obesity Society (Obesity Week). Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906 (GCGR/GLP-1R) in patients with T2D at Obesity Week. Phase 2 trial of BI 456906 in patients with non-alcoholic steatohepatitis (NASH). Received gross proceeds of DKK 786 million from a directed issue and private placement.
-
-
morning i klubben:)
-
22:21 synes det er væltet ind med nyheder i min Q3 - aktien er steget fra 75 til 190. Er op ca 30% i år mens markedet er ned 20%. Kan ikke liiige se hvad der mangler:)
(dasiglucagon) for injection.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind